Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
about
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsA multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remissionTrends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Initial therapy of mantle cell lymphomaSpecific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Clinicopathologic features and management of blastoid variant of mantle cell lymphoma.How to manage mantle cell lymphoma.Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.Front-line treatment of mantle cell lymphoma.Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q28075606-5EAEFDA7-B556-448F-B73D-50607D0ACB5EQ33399582-892FC477-1A75-4D40-849E-013886D8ACB2Q35211548-12981694-5328-440D-8A27-92ECE9D18AB5Q35236068-00858734-815F-44D4-9684-2E9535701E0FQ36612648-A0C07016-CA7D-4451-9332-FFF6D9ABD88FQ37210817-A2C0DFB6-1631-4D36-B560-41DDA76303FEQ38110232-94DA2772-41AF-4EFA-9C19-96AF570811BDQ38369665-12F02B41-10B7-4399-8521-3D0F9CC52A09Q39187610-8E0C4D2E-5C2D-4DF3-9F81-45123D73AB10Q39342854-109E1D74-7661-4B9B-9AB8-354E824C7DE9Q41350868-3B723764-9658-4428-8641-933044C4EA43Q42629494-4FE659CE-0EDD-486E-95D9-77554BFCA507Q48206720-7B17DA46-C72C-42D3-B3AC-FA05E989CDD0Q51146815-E68AF8DF-7C5C-43A6-9E3E-58996541F121Q57217007-B29768B7-A0A4-4D4E-95F2-56ADB31F41F7
P2860
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@ast
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@en
type
label
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@ast
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@en
prefLabel
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@ast
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@en
P2093
P2860
P1433
P1476
Evaluation of the (R)VAD+C reg ...... from the French GOELAMS group
@en
P2093
Abderrazak El Yamani
Bernadette Corront
Eric Deconinck
French GOELAMS Group
Ghandi Damaj
Gérard Lepeu
Hervé Maisonneuve
Jean François Rossi
Jean Pierre Vilque
Jerome Cornillon
P2860
P304
P356
10.3324/HAEMATOL.2009.011759
P577
2010-03-10T00:00:00Z